our platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs . we believe it costs more than $ 100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $ 3 million in the pre-clinical setting to approximately $ 150 million in phase iii clinical trials . simulating trials before executing them provides benefits to both pharmaceutical companies and patients . pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs . we plan to continue our efforts to expand our tumorgraft technology platform in order to expand our tos program . we have previously disclosed that our pos program would not be the focus of our growth moving forward and this plan remains unchanged . 16 results of operations the following table summarizes our operating results for the periods presented below ( dollars in thousands ) : replace_table_token_3_th oncology services revenue oncology services revenue for the years ended april 30 , 2020 and 2019 were $ 32.1 million and $ 27.1 million , respectively , an increase of $ 5.1 million , or 18.7 % . the increase in revenue is due to increased sales , both in number and size of studies , an increase in demand for our services , the growth of the platform , and expansion of our product line . additionally , customers are seeking more complex study designs and end point analysis testing , leading to larger contracts , which contributed to revenue growth . cost of oncology services cost of oncology services were $ 16.9 million and $ 14.3 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 2.6 million or 18.3 % . for the years ended april 30 , 2020 and 2019 , gross margins were 47.4 % and 47.3 % , respectively . the increase in cost of oncology services was mainly due to an increase in compensation , supply , and outsourced lab service expenses . with the exception of outsourced lab services , the overall expense increase is generally in line with the expected contribution based on the growth in revenue , study volume , and expansion into new services . gross margin varies based on timing differences between expense and revenue recognition and was impacted by the increase in costs ahead of revenue related to the increase in number of studies performed . additionally , the cost of outsourced lab services magnifies this effect . research and development research and development expense was $ 5.9 million and $ 4.8 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.1 million or 22.0 % . the increase is due to increased compensation and mice and lab supply expenses as we replenished the models in our bank and continued to develop new service capabilities and endpoint analysis testing . sales and marketing sales and marketing expense was $ 4.2 million and $ 3.1 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.2 million or 38.8 % . the increase is mainly due to compensation expense driven by the continued expansion of our sales force and commissions earned on increased sales . general and administrative general and administrative expense was $ 6.6 million and $ 4.7 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.9 million , or 41.4 % . the increase was mainly due to an increase in compensation expense which included a bonus awarded to the ceo . 17 goodwill impairment we recognized an impairment on goodwill of approximately $ 335,000 for the year ended april 30 , 2020. this charge was attributable to the company 's pos business operations . as disclosed in prior fiscal years , the pos business ceased to be the focus of our growth strategy moving forward . as a result of our annual evaluation of goodwill impairment , the company determined that the recording of the impairment charge was warranted . other expense other expense was $ 42,000 and $ 39,000 for the years ended april 30 , 2020 and 2019 , respectively . the current year expense is mainly due to foreign currency transaction losses and foreign fees offset by a gain on disposal of equipment . inflation inflation does not have a meaningful impact on the results of our operations . story_separator_special_tag whether it is more likely than not that a reporting unit 's carrying amount exceeds its fair value , referred to as a “ step zero ” approach . subsequently ( if necessary after step zero ) , an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value . under fasb 's asu 2014-02 , topic 350 , `` intangibles—goodwill and other `` goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value . the impairment evaluation test involves comparing the current fair value of each business unit to its carrying value , including goodwill . story_separator_special_tag the update is effective for public business entities for fiscal years beginning after december 15 , 2019 , and interim periods within those fiscal years . early adoption of the amendments in this update is permitted , including adoption in any interim period . we are currently assessing the impact of this update on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . in august 2018 , the fasb issued asu 2018-13 , fair value measurement ( asc 820 ) — disclosure framework-changes to the disclosure requirements for fair value measurement . asu 2018-13 removes certain disclosures , modifies certain disclosures and adds additional disclosures . asu 2018-13 is effective for annual periods , including interim periods within those annual periods , beginning after december 15 , 2019. early adoption is permitted . we are currently assessing the potential impact of the amendments in this asu on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . in december 2019 , the fasb issued asu 2019-12 , income taxes ( asc 740 ) — simplifying the accounting for income taxes . asu 2019-12 which modifies asc 740 to simplify the accounting for income taxes . the asu removes certain exceptions for recognizing deferred taxes for investments , performing intra-period allocation and calculating income taxes in interim periods . the asu also adds guidance to reduce complexity in certain areas , including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group . asu 2019-12 is effective for annual periods , including interim periods within those annual periods , beginning after december 15 , 2020. we are currently assessing the potential impact of this asu on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . recently adopted accounting pronouncements in february 2016 , the fasb issued asu no . 2016-02 , `` leases `` , ( topic 842 ) , which required the company to recognize lease assets and lease liabilities ( related to leases previously classified as operating under previous u.s. gaap ) on its consolidated balance sheet for all leases in excess of one year in duration . the asu was effective for the company on may 1 , 2019. the company elected to adopt asu 2016-02 using the modified retrospective method and , therefore , have not recast comparative periods presented in its unaudited consolidated financial statements . as permitted under asu 2016-02 , the company elected to account for the non-lease components together with the lease components as a single lease component . the company recorded an operating lease right-of-use ( `` rou `` ) asset of $ 3.2 million , net of deferred rent of $ 900,000 and an operating lease liability of $ 4.1 million as of may 1 , 2019. refer to `` note 13. leases `` for additional information . in august 2016 , the fasb issued asu no . 2016-15 , “ statement of cash flows : classification of certain cash receipts and cash payments ” . the new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows . asu no . 2016-15 provides guidance on eight specific cash flow issues . the new guidance was effective for fiscal years beginning after december 15 , 2017 and interim periods within those fiscal years . the company adopted asu 2016-15 on may 1 , 2018 and it did not have a material impact on its consolidated financial statements . 21 in november 2016 , the fasb issued asu no . 2016-18 , `` restricted cash ( a consensus of the fasb emerging issues task force ) `` ( `` asu 2016-18 `` ) , which addresses classification and presentation of changes in restricted cash on the statement of cash flows . asu 2016-18 requires an entity 's reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents . asu 2016-18 is effective for public business entities for annual and interim periods in fiscal years beginning after december 15 , 2017. the company adopted asu 2016-18 on may 1 , 2018 and did not have a material impact on its consolidated financial statements . in january 2017 , the fasb issued asu no . 2017-04 , “ intangibles - goodwill and other ” ( topic 350 ) : simplifying the test for goodwill impairment ( asu 2017-04 ) . this new standard simplifies how an entity is required to test goodwill for impairment by eliminating a step from the goodwill impairment test . asu 2017-04 allows for prospective application and is effective for fiscal years beginning after december 15 , 2019 , and interim periods therein with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after january 1 , 2017. the company adopted this guidance on may 1 , 2019 and it did not have an impact on its consolidated financial statements . in june 2018 , the fasb issued asu 2018-07 , `` compensation-stock compensation ( topic 718 ) : improvements to nonemployee share-based payment accounting `` . this asu expands the scope of topic 718 , compensation—stock compensation ( which currently only includes share-based payments to employees ) to include share-based payments issued to nonemployees for goods or services . under the new guidance , the existing employee guidance will apply to nonemployee share-based transactions ( as long as the transaction is not effectively a form of financing ) , with the exception of specific guidance related to the attribution of compensation cost . the cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services . the new accounting guidance

liquidity and capital resources our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products , working capital requirements , and other strategic initiatives . in the past , we have met these cash requirements through our cash on hand , working capital management , proceeds from certain private placements and public offerings of our securities and sales of products and services . for the years ended april 30 , 2020 and 2019 , the company had a net loss of approximately $ 2.0 million and net income of $ 128,000 , respectively . as of april 30 , 2020 , the company had an accumulated deficit of approximately $ 72.7 million , working capital of $ 1.4 million and cash of $ 8.3 million . we believe that our cash on hand , together with continued improved cash flows from operations , are adequate to fund operations through at least august 2021. should the company be required to raise additional capital , there can be no assurance that management would be successful in raising such capital on terms acceptable to us , if at all . cash flows the following discussion relates to the major components of our cash flows : cash flows from operating activities net cash provided by operating activities was $ 2.9 million and $ 1.9 million for the years ended april 30 , 2020 and 2019 , respectively . the increase in cash provided of $ 1.0 million relates to our revenue growth and increase in bookings , along with the timing of ordinary business operating activities . cash flows from investing activities net cash used in investing activities was $ 2.2 million and $ 834,000 for the years ended april 30 , 2020 and 2019 , respectively . these cash flows were used for the purchase and finance leasing of lab equipment . cash flows from financing activities net cash provided by financing activities was $ 4.4 million and $ 1.2 million for the years ended april 30 , 2020 and 2019 , respectively .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products , working capital requirements , and other strategic initiatives . in the past , we have met these cash requirements through our cash on hand , working capital management , proceeds from certain private placements and public offerings of our securities and sales of products and services . for the years ended april 30 , 2020 and 2019 , the company had a net loss of approximately $ 2.0 million and net income of $ 128,000 , respectively . as of april 30 , 2020 , the company had an accumulated deficit of approximately $ 72.7 million , working capital of $ 1.4 million and cash of $ 8.3 million . we believe that our cash on hand , together with continued improved cash flows from operations , are adequate to fund operations through at least august 2021. should the company be required to raise additional capital , there can be no assurance that management would be successful in raising such capital on terms acceptable to us , if at all . cash flows the following discussion relates to the major components of our cash flows : cash flows from operating activities net cash provided by operating activities was $ 2.9 million and $ 1.9 million for the years ended april 30 , 2020 and 2019 , respectively . the increase in cash provided of $ 1.0 million relates to our revenue growth and increase in bookings , along with the timing of ordinary business operating activities . cash flows from investing activities net cash used in investing activities was $ 2.2 million and $ 834,000 for the years ended april 30 , 2020 and 2019 , respectively . these cash flows were used for the purchase and finance leasing of lab equipment . cash flows from financing activities net cash provided by financing activities was $ 4.4 million and $ 1.2 million for the years ended april 30 , 2020 and 2019 , respectively .
```    
 Suspicious Activity Report : our platform provides a novel approach to simulating the results of human clinical trials used in developing oncology drugs . we believe it costs more than $ 100,000 per patient in oncology clinical trials and the typical cost for each phase of development per year increases from approximately $ 3 million in the pre-clinical setting to approximately $ 150 million in phase iii clinical trials . simulating trials before executing them provides benefits to both pharmaceutical companies and patients . pharmaceutical companies can lower the risk of spending resources on drugs that do not show significant anti-cancer activities and increase the chance that the clinical development path they pursue will be focused on an appropriate patient population and a successful combination with other drugs . we plan to continue our efforts to expand our tumorgraft technology platform in order to expand our tos program . we have previously disclosed that our pos program would not be the focus of our growth moving forward and this plan remains unchanged . 16 results of operations the following table summarizes our operating results for the periods presented below ( dollars in thousands ) : replace_table_token_3_th oncology services revenue oncology services revenue for the years ended april 30 , 2020 and 2019 were $ 32.1 million and $ 27.1 million , respectively , an increase of $ 5.1 million , or 18.7 % . the increase in revenue is due to increased sales , both in number and size of studies , an increase in demand for our services , the growth of the platform , and expansion of our product line . additionally , customers are seeking more complex study designs and end point analysis testing , leading to larger contracts , which contributed to revenue growth . cost of oncology services cost of oncology services were $ 16.9 million and $ 14.3 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 2.6 million or 18.3 % . for the years ended april 30 , 2020 and 2019 , gross margins were 47.4 % and 47.3 % , respectively . the increase in cost of oncology services was mainly due to an increase in compensation , supply , and outsourced lab service expenses . with the exception of outsourced lab services , the overall expense increase is generally in line with the expected contribution based on the growth in revenue , study volume , and expansion into new services . gross margin varies based on timing differences between expense and revenue recognition and was impacted by the increase in costs ahead of revenue related to the increase in number of studies performed . additionally , the cost of outsourced lab services magnifies this effect . research and development research and development expense was $ 5.9 million and $ 4.8 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.1 million or 22.0 % . the increase is due to increased compensation and mice and lab supply expenses as we replenished the models in our bank and continued to develop new service capabilities and endpoint analysis testing . sales and marketing sales and marketing expense was $ 4.2 million and $ 3.1 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.2 million or 38.8 % . the increase is mainly due to compensation expense driven by the continued expansion of our sales force and commissions earned on increased sales . general and administrative general and administrative expense was $ 6.6 million and $ 4.7 million for the years ended april 30 , 2020 and 2019 , respectively , an increase of $ 1.9 million , or 41.4 % . the increase was mainly due to an increase in compensation expense which included a bonus awarded to the ceo . 17 goodwill impairment we recognized an impairment on goodwill of approximately $ 335,000 for the year ended april 30 , 2020. this charge was attributable to the company 's pos business operations . as disclosed in prior fiscal years , the pos business ceased to be the focus of our growth strategy moving forward . as a result of our annual evaluation of goodwill impairment , the company determined that the recording of the impairment charge was warranted . other expense other expense was $ 42,000 and $ 39,000 for the years ended april 30 , 2020 and 2019 , respectively . the current year expense is mainly due to foreign currency transaction losses and foreign fees offset by a gain on disposal of equipment . inflation inflation does not have a meaningful impact on the results of our operations . story_separator_special_tag whether it is more likely than not that a reporting unit 's carrying amount exceeds its fair value , referred to as a “ step zero ” approach . subsequently ( if necessary after step zero ) , an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying value . under fasb 's asu 2014-02 , topic 350 , `` intangibles—goodwill and other `` goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value . the impairment evaluation test involves comparing the current fair value of each business unit to its carrying value , including goodwill . story_separator_special_tag the update is effective for public business entities for fiscal years beginning after december 15 , 2019 , and interim periods within those fiscal years . early adoption of the amendments in this update is permitted , including adoption in any interim period . we are currently assessing the impact of this update on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . in august 2018 , the fasb issued asu 2018-13 , fair value measurement ( asc 820 ) — disclosure framework-changes to the disclosure requirements for fair value measurement . asu 2018-13 removes certain disclosures , modifies certain disclosures and adds additional disclosures . asu 2018-13 is effective for annual periods , including interim periods within those annual periods , beginning after december 15 , 2019. early adoption is permitted . we are currently assessing the potential impact of the amendments in this asu on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . in december 2019 , the fasb issued asu 2019-12 , income taxes ( asc 740 ) — simplifying the accounting for income taxes . asu 2019-12 which modifies asc 740 to simplify the accounting for income taxes . the asu removes certain exceptions for recognizing deferred taxes for investments , performing intra-period allocation and calculating income taxes in interim periods . the asu also adds guidance to reduce complexity in certain areas , including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group . asu 2019-12 is effective for annual periods , including interim periods within those annual periods , beginning after december 15 , 2020. we are currently assessing the potential impact of this asu on our consolidated financial statements and do not expect a material impact on our consolidated financial statements . recently adopted accounting pronouncements in february 2016 , the fasb issued asu no . 2016-02 , `` leases `` , ( topic 842 ) , which required the company to recognize lease assets and lease liabilities ( related to leases previously classified as operating under previous u.s. gaap ) on its consolidated balance sheet for all leases in excess of one year in duration . the asu was effective for the company on may 1 , 2019. the company elected to adopt asu 2016-02 using the modified retrospective method and , therefore , have not recast comparative periods presented in its unaudited consolidated financial statements . as permitted under asu 2016-02 , the company elected to account for the non-lease components together with the lease components as a single lease component . the company recorded an operating lease right-of-use ( `` rou `` ) asset of $ 3.2 million , net of deferred rent of $ 900,000 and an operating lease liability of $ 4.1 million as of may 1 , 2019. refer to `` note 13. leases `` for additional information . in august 2016 , the fasb issued asu no . 2016-15 , “ statement of cash flows : classification of certain cash receipts and cash payments ” . the new standard attempts to reduce diversity in practice in how cash receipts and cash payments are presented and classified in the statement of cash flows . asu no . 2016-15 provides guidance on eight specific cash flow issues . the new guidance was effective for fiscal years beginning after december 15 , 2017 and interim periods within those fiscal years . the company adopted asu 2016-15 on may 1 , 2018 and it did not have a material impact on its consolidated financial statements . 21 in november 2016 , the fasb issued asu no . 2016-18 , `` restricted cash ( a consensus of the fasb emerging issues task force ) `` ( `` asu 2016-18 `` ) , which addresses classification and presentation of changes in restricted cash on the statement of cash flows . asu 2016-18 requires an entity 's reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents . asu 2016-18 is effective for public business entities for annual and interim periods in fiscal years beginning after december 15 , 2017. the company adopted asu 2016-18 on may 1 , 2018 and did not have a material impact on its consolidated financial statements . in january 2017 , the fasb issued asu no . 2017-04 , “ intangibles - goodwill and other ” ( topic 350 ) : simplifying the test for goodwill impairment ( asu 2017-04 ) . this new standard simplifies how an entity is required to test goodwill for impairment by eliminating a step from the goodwill impairment test . asu 2017-04 allows for prospective application and is effective for fiscal years beginning after december 15 , 2019 , and interim periods therein with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after january 1 , 2017. the company adopted this guidance on may 1 , 2019 and it did not have an impact on its consolidated financial statements . in june 2018 , the fasb issued asu 2018-07 , `` compensation-stock compensation ( topic 718 ) : improvements to nonemployee share-based payment accounting `` . this asu expands the scope of topic 718 , compensation—stock compensation ( which currently only includes share-based payments to employees ) to include share-based payments issued to nonemployees for goods or services . under the new guidance , the existing employee guidance will apply to nonemployee share-based transactions ( as long as the transaction is not effectively a form of financing ) , with the exception of specific guidance related to the attribution of compensation cost . the cost of nonemployee awards will continue to be recorded as if the grantor had paid cash for the goods or services . the new accounting guidance

